Many new cancer drugs are entering clinical practice and clinical trials. Many GIST patients are no longer responding to Gleevec or Sutent and thus are looking for clinical trials. Understanding strategies and grouping these new drugs into classes with other similar drugs may help patients understand some of their choices.
Pfizer Pharmaceuticals is offering Sutent in Touch, a program to support GIST patients on its drug Sutent. The program is free and patients can sign up by calling (1-877-578-8368). Sutent in Touch links patients to Oncology [...]
Trial investigators for the Global Phase 3 GRID trial reported that the Bayer Pharmaceuticals’ drug regorafenib (BAY 73-4506) has the potential to fill the unmet need for advanced GIST patients progressing after imatinib and sunitinib. [...]